Open Access

LASP2 suppressed malignancy and Wnt/β‑catenin signaling pathway activation in bladder cancer

  • Authors:
    • Rongquan Yang
    • Zeming Liao
    • Yong Cai
    • Jingjing Kong
  • View Affiliations

  • Published online on: October 9, 2018     https://doi.org/10.3892/etm.2018.6836
  • Pages: 5215-5223
  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

LIM and SH3 Protein 2 (LASP2), a member of the nebulin family of actin‑binding proteins, is associated with the development of cancers. However, little was known about the role of LASP2 in human bladder cancer. In the current study, LASP2 expression was evaluated by reverse transcription‑quantitative polymerase chain reaction analysis in bladder cancer cell lines and tissue samples. The role of LASP2 in cancer cell proliferation, migration and invasion, and angiogenesis was explored. The association between prognostic outcomes and LASP2 expression were examined using Kaplan‑Meier analysis. LASP2 expression was decreased in bladder cancer cells and tissues. LASP2 expression was associated with tumor size (P=0.016) and T classification (P=0.001). Patients with lower LASP2 expression had shorter overall and recurrent‑free survival times. Overexpression of LASP2 inhibited and silencing of LASP2 promoted the proliferation, migration and invasion of bladder cancer cells, and angiogenesis in bladder cancer. Furthermore, it was determined that the tumor suppressing effect of LASP2 may be associated with the inactivation of the Wnt/β‑catenin signaling pathway. LASP2 may represent a novel and useful prognostic indicator, and could serve as a potential therapeutic target for bladder cancer.
View Figures
View References

Related Articles

Journal Cover

December-2018
Volume 16 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yang R, Liao Z, Cai Y and Kong J: LASP2 suppressed malignancy and Wnt/β‑catenin signaling pathway activation in bladder cancer. Exp Ther Med 16: 5215-5223, 2018
APA
Yang, R., Liao, Z., Cai, Y., & Kong, J. (2018). LASP2 suppressed malignancy and Wnt/β‑catenin signaling pathway activation in bladder cancer. Experimental and Therapeutic Medicine, 16, 5215-5223. https://doi.org/10.3892/etm.2018.6836
MLA
Yang, R., Liao, Z., Cai, Y., Kong, J."LASP2 suppressed malignancy and Wnt/β‑catenin signaling pathway activation in bladder cancer". Experimental and Therapeutic Medicine 16.6 (2018): 5215-5223.
Chicago
Yang, R., Liao, Z., Cai, Y., Kong, J."LASP2 suppressed malignancy and Wnt/β‑catenin signaling pathway activation in bladder cancer". Experimental and Therapeutic Medicine 16, no. 6 (2018): 5215-5223. https://doi.org/10.3892/etm.2018.6836